Xcout IntelIterum Therapeutics plc competitors & alternatives
The 12 closest competitors and alternatives to Iterum Therapeutics plc among biotechnology companies — ranked by similarity to what Iterum Therapeutics plc actually does, not by market-cap band.
Subscribe to see Iterum Therapeutics plc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Iterum Therapeutics plc
Iterum Therapeutics plc, an Irish pharmaceutical company founded in Dublin in 2015, is dedicated to the development and commercialization of treatments for bacterial infections that are resistant to existing drugs. Operating in Ireland, Bermuda, and the United States, the firm currently markets ORLYNVAH, an oral penem antibiotic. This medication is prescribed for adult women experiencing uncomplicated urinary tract infections (uUTIs) caused by specific microorganisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, particularly when alternative oral antibacterial treatments are limited or unavailable. Furthermore, Iterum is actively progressing sulopenem, an innovative anti-infective compound. This drug, being developed in both oral and intravenous formulations, is intended to address a range of conditions, including uncomplicated and complicated urinary tract infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. The company is currently in a state of reorganization.
Iterum Therapeutics plc at a glance
Iterum Therapeutics plc is a biotechnology company headquartered in Dublin, Ireland. It is publicly listed (ITRMF) with a market capitalisation of $532. Xcout tracks 15 named people at Iterum Therapeutics plc, including Christine R. Coyne (Chief Commercial Officer).
Iterum Therapeutics plc leadership
- Christine R. CoyneChief Commercial Officer
- Steven I. AroninSenior Vice President & Head of Clinical Development
- Tom LoughmanSenior Vice President of Technical Operations
- Kevin DaltonSenior Director of Legal Affairs & Company Secretary
- David G. KellyDirector and Chairman of the Board
- Beth HechtDirector
9 more named people on record for Iterum Therapeutics plc, with roles, board committees and tenure — see the full roster →
Iterum Therapeutics plc funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $78.1M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Iterum Therapeutics plc competitors
Ranked by semantic similarity — how close each company is to Iterum Therapeutics plc by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotechnology company
Thioredoxin Systems AB is a Swedish biotechnology and pharmaceutical company based in Solna, developing a novel antibiotic regimen to treat multidrug-resistant and complicated urinary tract infections caused by pathogenic bacteria.
Biotech
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Similar biotechnology company
Utility Therapeutics is a biotechnology company focused on developing antibiotics for the treatment of urinary tract infections in the United States. The company developed the FDA-approved product Pivya for uncomplicated urinary tract infections. In 2024, Utility Therapeutics was acquired by Alembic Pharmaceuticals.
Similar biotechnology company
TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.
Similar biotechnology company
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Biotech
Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. Founded in 2015, the company is dedicated to revolutionizing healthcare through novel drug discovery and innovation.
Similar biotechnology company
Akagera Medicines is a private Delaware-registered company headquartered in Boston, Massachusetts. The company develops novel and patented liposomal formulations of antibacterial drugs.
Biotech
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
Biotech
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Biotech
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
Similar biotechnology company
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Iterum Therapeutics plc and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Iterum Therapeutics plcand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →